Acurx Pharmaceuticals, Inc.
ACXP evidence brief
What we can confirm
- Market Cap:
- $6.0M
What it means
What to watch
Prepared research question
What matters most for ACXP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACXP
Acurx Pharmaceuticals, Inc. (ACXP) is a clinical-stage biopharmaceutical company developing ibezapolstat, a DNA polymerase IIIC inhibitor for the treatment and prevention of recurrent Clostridioides difficile infection (rCDI), with a Phase 2 trial underway and a planned Phase 3 registration study.
Key risk: Cash runway limited
Market Cap
$6.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Acurx Pharmaceuticals, Inc..
Acurx Pharmaceuticals, Inc. (ACXP) is a clinical-stage biopharmaceutical company developing ibezapolstat, a DNA polymerase IIIC inhibitor for the treatment and prevention of recurrent Clostridioides difficile infection (rCDI), with a Phase 2 trial underway and a planned Phase 3 registration study.
- Lead candidate ibezapolstat (ACX-362E) is a Phase 3-stage oral DNA polymerase IIIC inhibitor targeting Clostridioides difficile infection recurrence [pipeline].
- As of March 31, 2026, the company reported cash of approximately $9.3 million [sec_mda · as of 2026-05-11].
- Latest reported financials (as of 2026-06-30) show net income of -$2.3M and shareholders' equity of $8.2M [sec].
- A Phase 2 interventional, open-label, single-arm trial (IBZ-PATHFINDER) for rCDI began in Q2 2026, with first patient enrollment expected in Q4 2026 [catalyst][sec_mda · as of 2026-08-13].
- The company plans to seek FDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) after a successful pivotal Phase 3 study [sec_mda · as of 2026-08-13].
What works
- Ibezapolstat has received Fast Track designation from the FDA, which may expedite development and review [pipeline].
- Preclinical data presented at IDWeek October 2025 suggest microbiome selectivity may be a class effect of DNA pol IIIC inhibitors, potentially offering a differentiation advantage over broad-spectrum antibiotics [sec_mda · as of 2026-08-13].
- The company has a clear regulatory pathway under the LPAD, which is designed for targeted antibacterial drugs with limited patient populations [sec_mda · as of 2026-08-13].
What to weigh
- The company is pre-revenue and reported a net loss of $2.3M for the quarter ended June 30, 2026, reflecting ongoing R&D spending without approved product sales [sec].
- Cash of $9.3M as of March 31, 2026, may be insufficient to complete the planned Phase 2 and Phase 3 trials without additional financing [sec_mda · as of 2026-05-11].
- The competitive landscape includes at least two other Phase 3 candidates (Vedanta VE303 and AstraZeneca AZD5148), creating uncertainty about market share if ibezapolstat is approved [pipeline].
- The company relies on third-party suppliers and manufacturers, which introduces operational and regulatory risks [sec_mda · as of 2026-09-08].
From the filings
Quoted directly from source documents.
Ibezapolstat is a DNA polymerase IIIC inhibitor for C. difficile infection recurrence.
“Blocks the active site of DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death”
Pipeline
Cash position as of March 31, 2026.
“As of March 31, 2026, we had cash of approximately $9.3 million.”
SEC MD&A · May 11, 2026
Phase 2 trial start and first patient enrollment timeline.
“Trial start up activities began in the second quarter, and first patient enrollment is expected in the fourth quarter of this year.”
SEC MD&A · August 13, 2026
Plan to seek FDA approval under LPAD.
“Following a successful pivotal Phase 3 study, the Company plans to seek the United States Food and Drug Administration's approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for treatment and prevention of rCDI.”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2026-08-06 · Phase 2 Start (IBZ-PATHFINDER) — A Phase 2 interventional, open-label, single-arm trial of oral ibezapolstat for treatment and reduction of recurrent C. difficile infection in patients with multiple recurrences.
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash of $9.3M as of March 31, 2026, may not cover full Phase 2/3 costs without further financing [sec_mda · as of 2026-05-11].
- Pre-revenue stage — Net loss of $2.3M in Q2 2026 with no approved product sales; reliant on equity/debt for operations [sec].
- Competitive pressure — At least two Phase 3 competitors (Vedanta VE303, AstraZeneca AZD5148) targeting same indication [pipeline].
- Regulatory and manufacturing risk — Dependence on third-party suppliers and manufacturers for drug substance and product [sec_mda · as of 2026-09-08].
What to watch
- First patient enrollment in the Phase 2 IBZ-PATHFINDER trial, expected in Q4 2026 [sec_mda · as of 2026-08-13].
- Cash position updates in subsequent quarterly filings, especially after the April 2026 registered direct offering [sec_mda · as of 2026-08-13].
- Any announcements regarding a Phase 3 registration trial design or partnership for ibezapolstat [sec_mda · as of 2026-08-13].
- Competitive developments from Vedanta Biosciences (VE303) and AstraZeneca (AZD5148) in rCDI [pipeline].
Sources: Catalysts · Pipeline · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Acurx Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Acurx Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
22
Total value held
$605K
| Holder | Shares | Value |
|---|---|---|
| jane street group, llc | 54,642 | $203K |
| vanguard capital management llc | 31,099 | $115K |
| geode capital management, llc | 24,819 | $92K |
| vanguard fiduciary trust co | 16,205 | $60K |
| prospect financial services llc | 13,785 | $51K |
| morgan stanley | 6,500 | $24K |
| ubs group ag | 6,312 | $23K |
| wells fargo & company/mn | 2,300 | $9K |
| westside investment management, inc. | 1,650 | $6K |
| nbc securities, inc. | 1,500 | $6K |
Showing top 10 of 22 institutional holders of Acurx Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.2%
- Days to cover
- 0.6
- Shares short
- 114,951
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACXP short interestFrequently asked questions
What is the AI investment thesis for Acurx Pharmaceuticals, Inc.?
Acurx Pharmaceuticals, Inc. (ACXP) is a clinical-stage biopharmaceutical company developing ibezapolstat, a DNA polymerase IIIC inhibitor for the treatment and prevention of recurrent Clostridioides difficile infection (rCDI), with a Phase 2 trial underway and a planned Phase 3 registration study.
Who is the CEO of Acurx Pharmaceuticals, Inc.?
Mr. David P. Luci C.P.A., Esq., J.D. is the chief executive officer of Acurx Pharmaceuticals, Inc. (ACXP).
Where is Acurx Pharmaceuticals, Inc. headquartered?
Acurx Pharmaceuticals, Inc. (ACXP) is headquartered in Staten Island, NY, United States.
What therapeutic areas does Acurx Pharmaceuticals, Inc. focus on?
Acurx Pharmaceuticals, Inc. develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.